These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 32614428)

  • 1. Early glycaemic changes after initiation of oral antidiabetic medication and risk of major adverse cardiovascular events: results from a large primary care population of patients with type 2 diabetes.
    Ghouse J; Blanche P; Skov MW; Lind B; Vaag A; Kanters JK; Svendsen JH; Køber L; Olesen MS; Gerds TA; Holst AG; Nielsen JB
    Eur Heart J Cardiovasc Pharmacother; 2021 Nov; 7(6):486-495. PubMed ID: 32614428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of diabetes duration on the relationship between glycaemic control and risk of death in older adults with type 2 diabetes.
    Ghouse J; Isaksen JL; Skov MW; Lind B; Svendsen JH; Kanters JK; Olesen MS; Holst AG; Nielsen JB
    Diabetes Obes Metab; 2020 Feb; 22(2):231-242. PubMed ID: 31596048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early and ongoing stable glycaemic control is associated with a reduction in major adverse cardiovascular events in people with type 2 diabetes: A primary care cohort study.
    Whyte MB; Joy M; Hinton W; McGovern A; Hoang U; van Vlymen J; Ferreira F; Mount J; Munro N; de Lusignan S
    Diabetes Obes Metab; 2022 Jul; 24(7):1310-1318. PubMed ID: 35373891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of oral diabetes medications on glycated haemoglobin (HbA1c) in Asians in primary care: a retrospective cohort real-world data study.
    Fang HSA; Gao Q; Tan WY; Lee ML; Hsu W; Tan NC
    BMC Med; 2022 Jan; 20(1):22. PubMed ID: 35078484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2).
    Zinman B; Marso SP; Poulter NR; Emerson SS; Pieber TR; Pratley RE; Lange M; Brown-Frandsen K; Moses A; Ocampo Francisco AM; Barner Lekdorf J; Kvist K; Buse JB;
    Diabetologia; 2018 Jan; 61(1):48-57. PubMed ID: 28913575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visit-to-Visit Variability of Hemoglobin A
    Ghouse J; Skov MW; Kanters JK; Lind B; Isaksen JL; Blanche P; Haunsø S; Køber L; Svendsen JH; Olesen MS; Holst AG; Gerds TA; Nielsen JB
    Diabetes Care; 2019 Jan; 42(1):134-141. PubMed ID: 30352898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediabetes Defined by First Measured HbA
    Yahyavi SK; Snorgaard O; Knop FK; Schou M; Lee C; Selmer C; Gislason G; Torp-Pedersen C; Blomberg Jensen M; Nissen Bonde A
    Diabetes Care; 2021 Dec; 44(12):2767-2774. PubMed ID: 34675054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A higher non-severe hypoglycaemia rate is associated with an increased risk of subsequent severe hypoglycaemia and major adverse cardiovascular events in individuals with type 2 diabetes in the LEADER study.
    Heller SR; Geybels MS; Iqbal A; Liu L; Wagner L; Chow E
    Diabetologia; 2022 Jan; 65(1):55-64. PubMed ID: 34704120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihyperglycaemic treatment patterns, observed glycaemic control and determinants of treatment change among patients with type 2 diabetes in the United Kingdom primary care: a retrospective cohort study.
    Maguire A; Mitchell BD; Ruzafa JC
    BMC Endocr Disord; 2014 Aug; 14():73. PubMed ID: 25163796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycated haemoglobin levels among 3295 hospitalized COVID-19 patients, with and without diabetes, and risk of severe infection, admission to an intensive care unit and all-cause mortality.
    Alhakak A; Butt JH; Gerds TA; Fosbøl EL; Mogensen UM; Krøll J; Pallisgaard JL; Gislason GH; Torp-Pedersen C; Køber L; Weeke PE
    Diabetes Obes Metab; 2022 Mar; 24(3):499-510. PubMed ID: 34779086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cause-specific risk of major adverse cardiovascular outcomes and hypoglycemic in patients with type 2 diabetes: a multicenter prospective cohort study.
    Sun B; He F; Sun L; Zhou J; Shen J; Xu J; Wu B; Liu R; Wang X; Xu H; Chen X; Zhou H; Liu Z; Zhang W
    Endocrine; 2019 Jan; 63(1):44-51. PubMed ID: 30121774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations of HbA1c and educational level with risk of cardiovascular events in 32,871 drug-treated patients with Type 2 diabetes: a cohort study in primary care.
    Östgren CJ; Sundström J; Svennblad B; Lohm L; Nilsson PM; Johansson G
    Diabet Med; 2013 May; 30(5):e170-7. PubMed ID: 23350893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes.
    Paul SK; Klein K; Thorsted BL; Wolden ML; Khunti K
    Cardiovasc Diabetol; 2015 Aug; 14():100. PubMed ID: 26249018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects on clinical outcomes of intensifying triple oral antidiabetic drug (OAD) therapy by initiating insulin versus enhancing OAD therapy in patients with type 2 diabetes: A nationwide population-based, propensity-score-matched cohort study.
    Kuo S; Yang CT; Wu JS; Ou HT
    Diabetes Obes Metab; 2019 Feb; 21(2):312-320. PubMed ID: 30187666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.
    Sattar N; Lee MMY; Kristensen SL; Branch KRH; Del Prato S; Khurmi NS; Lam CSP; Lopes RD; McMurray JJV; Pratley RE; Rosenstock J; Gerstein HC
    Lancet Diabetes Endocrinol; 2021 Oct; 9(10):653-662. PubMed ID: 34425083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Legacy effect of intensive glucose control on major adverse cardiovascular outcome: Systematic review and meta-analyses of trials according to different scenarios.
    Prattichizzo F; de Candia P; De Nigris V; Nicolucci A; Ceriello A
    Metabolism; 2020 Sep; 110():154308. PubMed ID: 32628943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between usual glycated haemoglobin and cardiovascular disease in patients with type 2 diabetes mellitus: A 10-year diabetes cohort study.
    Wan EY; Yu EY; Chen JY; Wong IC; Chan EW; Lam CL
    Diabetes Obes Metab; 2020 Dec; 22(12):2325-2334. PubMed ID: 32744402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of hemoglobin A1c levels on cardiovascular events and all-cause mortality in people with diabetes over 70 years of age. A prospective study.
    Orozco-Beltrán D; Navarro-Pérez J; Cebrián-Cuenca AM; Álvarez-Guisasola F; Caride-Miana E; Mora G; Quesada JA; López-Pineda A; Cardona-Llorens AF; Redón J; Gil-Guillen VF; Fernández A; Carratalá-Munuera C
    Prim Care Diabetes; 2020 Dec; 14(6):678-684. PubMed ID: 32605878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycated hemoglobin variability and the risk of cardiovascular events in patients with prediabetes and type 2 diabetes mellitus: A post-hoc analysis of a prospective and multicenter study.
    Manosroi W; Phimphilai M; Waisayanand N; Buranapin S; Deerochanawong C; Gunaparn S; Phrommintikul A; Wongcharoen W;
    J Diabetes Investig; 2023 Dec; 14(12):1391-1400. PubMed ID: 37610280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.